Buprenorphine Hydrochloride and Naloxone Hydrochloride

The FDA has granted approval for Opvee, the first intranasal nalmefene therapy for emergency treatment of opioid overdose in patients 12 and older. Developed by Opiant Pharma and now owned by Indivior, the drug offers a longer-acting alternative to existing naloxone treatments amid the ongoing opioid crisis that claimed over 103,000 lives in the past year.

Aquestive Therapeutics is on track to submit its NDA for Anaphylm sublingual film in Q1 2025, aiming to provide the first orally delivered epinephrine for severe allergic reactions.

UW-Madison researchers are launching a groundbreaking study to explore the use of ketamine, combined with psychotherapy, for treating adolescents with PTSD. This early-stage trial aims to assess the safety and potential therapeutic benefits of ketamine in a controlled setting, marking a significant step in psychedelic research for mental health conditions.

GLP-1 agonists, initially for diabetes and obesity, are being explored for their potential in treating substance use disorders by targeting brain mechanisms.

The FDA has approved Protega Pharmaceuticals' Roxybond 10mg for managing severe pain when alternative treatments are inadequate.